Studies on Biomarkers for Mild Cognitive Impairment Conversion to Dementia

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Mild cognitive impairment (MCI) represents a transitional stage between healthy aging and dementia, and affects more than 15% of the population over the age of 60 in China. About 15% patients with MCI could progress into dementia after two years and about one-third develop into dementia within five years, which will lead to suffering, as well as staggering economic and care burden. So, exploring the predicting biomarkers from MCI to dementia to identify and delay progression to dementia at an early stage is of great social and clinical significance. Some reports based on a single neural biomarker suggest that risk models can predict the conversion of MCI to dementia, but no widely recognized prediction models basing on multiple complex markers have been used in clinical practice. The objectives of this study are to outline the spectrum of MCI transforming into dementia through a 5-year prospective longitudinal cohort study; Secondly, screening biomarkers for MCI transmit to dementia are based on clinical symptoms, neuropsychology, neuroimaging, neuroelectrophysiology, and humoral markers tests data.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 85
Healthy Volunteers: t
View:

• Male or female patients aged ≥50 and ≤85 years;

⁃ Meet the diagnostic criteria for dementia or MCI; ③ Neuropsychological score: MMSE 15-28 points, CDR≤1 point; ④ The patients and their families were informed and signed the informed consent.

Locations
Other Locations
China
Xuan Wu Hospital of Capital Medical University
RECRUITING
Beijing
Contact Information
Primary
Cuibai Wei
weicb@xwhosp.org
83198319
Time Frame
Start Date: 2023-02-28
Estimated Completion Date: 2028-02-28
Participants
Target number of participants: 900
Treatments
MCI progression
MCI-P (Compared with the baseline, MMSE score declined \> 4 points per year)
MCI stabilization
MCI-S (Compared with the baseline, MMSE score decreased \< 4 points per year)
Related Therapeutic Areas
Sponsors
Collaborators: Tianjin Huanhu Hospital, First Hospital of Shijiazhuang City, Affiliated Zhongshan Hospital of Dalian University, Chongqing Medical University, Beihang University, Jilin University, Chinese PLA General Hospital
Leads: Cuibai Wei,Clinical Professor

This content was sourced from clinicaltrials.gov